drugset
drugset / Trial / NCT04150172

To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

NCT04150172 ↗

Phase 1 Completed 40 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelOther

Summary

This is a randomized, open label, multiple dose, crossover study to compare the safety and Pharmacokinetics (PKs) between two rebamipide formulations after multiple oral doses of "rebamipide SR 150 mg" and "rebamipide IR 100 mg" in healthy adult volunteers.

Timeline

Start
2019-04-22
Primary completion
2019-05-01
Completion
2019-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 100 mg Oral
Subject Rebamipide Small molecule 150 mg Oral

Indications

No indication recorded.